The trial enrolled adults with type 2 diabetes at increased cardiovascular risk, and the cohort skewed older with metabolic comorbidity. Mean age was 63.1 years. Baseline glycaemic control averaged an HbA1c of 8.2% and mean BMI was 33 kg/m2. Investigators reported that 85.9% of participants had established cardiovascular disease and 37.6% had chronic kidney disease. These baseline prevalences frame event expectations and contextualise subsequent outcome rates. The source did not provide granular renal function strata or detailed eGFR distributions in the abstract.
The primary outcome assessed time to the first occurrence of a four-component major adverse cardiovascular event (MACE-4): cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalisation for unstable angina. Over a median follow-up of 2 years, 57 of 1358 participants assigned to orforglipron experienced a MACE-4 event (4.2%), compared with 67 of 1343 in the insulin glargine arm (5.0%). The reported hazard ratio was 0.84 with a 95% CI of 0.59–1.20. Based on the prespecified non-inferiority margin (upper 95% CI <1.8), investigators concluded that orforglipron met non-inferiority versus insulin glargine for cardiovascular safety, with p<0.0001 for non-inferiority.
Those numbers indicate comparable event rates between an oral non-peptide GLP-1 receptor agonist and a daily basal insulin comparator across a broad, high-risk population. The abstract did not report event adjudication procedures in detail, nor did it present subgroup hazard ratios by age, sex, baseline cardiovascular status, or concomitant SGLT2 inhibitor use.
Adverse events diverged between arms by predictable mechanism. Gastrointestinal events were the most frequent adverse event with orforglipron, occurring in 851 of 1371 participants (62.1%). Investigators noted gastrointestinal events as the leading cause of orforglipron discontinuation. By contrast, gastrointestinal complaints were reported in 193 of 1355 participants (14.2%) in the insulin glargine arm.
Clinically significant or severe hypoglycaemia, defined in the abstract as glucose <3 mmol/L (54 mg/dL), occurred less often with orforglipron. Ninety-three of 1371 participants (6.8%) in the orforglipron group experienced such events versus 260 of 1355 participants (19.2%) assigned to insulin glargine. The pattern aligns with the oral GLP-1 receptor agonist’s glucose-dependent mechanism compared with exogenous insulin dosing and titration.
The abstract did not report detailed severity gradations for gastrointestinal adverse events, nor daily incidence patterns or the proportion of events leading to hospitalisation, beyond noting discontinuation as a consequence.
Sixty-two deaths occurred during the study period. Nineteen deaths (1.4%) occurred in participants receiving orforglipron and 43 deaths (3.2%) in those receiving insulin glargine. Investigators reported that all deaths except one (in the insulin glargine group) were deemed unrelated to study treatment. The abstract does not provide cause-specific mortality breakdowns beyond these counts, and it does not present temporal relationships between deaths and treatment initiation or dosage adjustments.
ACHIEVE-4 was a phase 3, event-driven, multicentre, randomised, open-label, active-comparator, parallel-group trial conducted at 317 sites across 16 countries and territories. The protocol randomised 2749 participants in a 1:1 ratio: 1371 to orforglipron and 1378 to insulin glargine. Eligibility required HbA1c between 7.0% and 10.5% and BMI ≥25 kg/m2, with background therapy permitted up to three glucose-lowering agents (metformin, a sulfonylurea, and/or an SGLT2 inhibitor).
Orforglipron was administered orally at the maximum tolerated dose up to a 36 mg capsule (stated to be equivalent to a 17.2 mg tablet). Insulin glargine was given as a titrated once-daily injectable. The primary and safety analyses included all participants who received at least one dose of assigned treatment and used data from baseline until withdrawal or study completion, independent of adherence.
The abstract did not present the full CONSORT-style flow diagram or detailed adherence metrics in the text presented, and it did not specify individual dose-escalation schedules or average achieved doses beyond the maximum tolerated dose statement.
The published abstract confirms non-inferiority of orforglipron versus insulin glargine for MACE-4 over a median of 2 years, but it leaves several practical questions open. The source did not include extensive subgroup analyses or cause-specific mortality tables in the abstract. It did not supply long-term follow-up beyond the median two-year window, nor granular data on adjudication processes, event timing relative to treatment initiation, or detailed dose-exposure relationships. Those elements will require consultation of the full text, supplementary appendices, or subsequent publications for clinicians seeking implementation-level detail.